Monday, January 16, 2023

Zydus Lifesciences arm gets USFDA nod to market generic Levomilnacipran ER capsules

Zydus Lifesciences arm gets USFDA nod to market generic Levomilnacipran ER capsules The tentative approval granted by the US Food and Drug Administration (USFDA) to Zydus Pharmaceuticals (USA) Inc is to market Levomilnacipran extended-release capsules of strengths 20 mg, 40 mg, 80 mg, and 120 mg, the company said in a regulatory filing.

from Moneycontrol Business News https://ift.tt/oXnUWSp
at
Labels: , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

LTIMindtree Q4 Preview: Lower pass-through revenue seen impacting growth marginally

A compilation of estimates suggests the company#39;s Q4 FY24 net profit is projected to decline by 2.2 percent quarter on quarter to Rs 1,1...